Skip to main content

Table 1 Patients characteristics for ten monitored SCLC patients with confirmed SIADH

From: A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan

Case Gender Age at diagnosis (years) Sodium level at therapy start (mmol/l) TNM Overall survival (months)
1 m 52 121 T4 N1 M1b (brain) 19
2 m 70 121 T4 N3 M1b (hepatic, osseous, pleura) 8
3 m 66 118 T4 N3 M1b (cervical, pulmonal, osseous) 8
4 f 62 115 T4 N2 M0 20, lives
5 f 62 118 T4 N3 M1b (hepatic) 11
6 m 66 120 T3 N2 M0 11
7 m 50 116 T2a N1 M0 2
8 f 63 117 T4 N3 M0 11, lives
9 m 71 122 T4 N3 M1a 5
10 m 65 117 T4 N3 M1b (hepatic, osseous) 10
  1. (Localisation of the metastases indicated in parentheses).